Biomedical subjects

K D Sermon

Publications and source records attributed to K D Sermon.

4 recordsLinked to original sources

PubMed2006

ESHRE PGD Consortium data collection VI: cycles from January to December 2003 with pregnancy follow-up to October 2004.

The sixth report of the ESHRE PGD Consortium is presented, relating to cycles collected for the calendar year 2003 and follow-up of the pregnancies and babies born up to October 2004. Since the beginning of the data collections, there has been a steady rise in the number of cycles, pregnancies and babies reported. For this report, 50 centres participated, reporting on 2984 cycles, 501 pregnancies and 373 babies born. Five hundred and twenty-nine cycles were reported for chromosomal abnormalities, 516 cycles were reported for monogenic diseases, 137 cycles were reported for sexing for X-linked diseases, 1722 cycles were reported for preimplantation genetic screening (PGS) and 80 cycles were reported for social sexing. Data VI is compared to the cumulative data for data collections I-V.

Abortion, Spontaneous↗

PubMed2006

Preimplantation genetic diagnosis.

Preimplantation genetic diagnosis (PGD) is an early form of prenatal diagnosis whereby embryos obtained in vitro are tested for the presence of a certain genetic disease. Patients who are at risk to have a child with a genetic disease can thus avoid a prenatal diagnosis and a possible termination of pregnancy. At the Centres for Medical Genetics and Reproductive Medicine, we have applied PGD for monogenic diseases since 1993 and are now one of the largest in the world. In this paper, the theoretical and technical side of PGD will first be explained. Thereafter, our activity since 1993 will be described. At the end of 2004, we had carried out 713 cycles for 319 patients for 54 different indications, leading to 159 (22 %) clinical pregnancies. The ESHRE PGD Consortium, of which I am chairperson, has been collating data on PGD from PGD centres from the whole world. This has led to the publication of four reports that are considered widely as important documents, as well as a comprehensive set of guidelines. Finally, there is the aspect of the scientific research ensuing from the PGD programme. The research into the causes of instability of triplet repeats in genetic diseases such as DM1 and Huntington's disease has made significant progress. The embryonic stem cell lab was started up in 2002, and has already succeeded in deriving five new lines, as well as progressing significantly into the research in differentiation to muscle cells and the behaviour of triplet repeats in totipotent stem cells.

Chromosome Aberrations↗

PubMed2005

ESHRE PGD Consortium data collection V: cycles from January to December 2002 with pregnancy follow-up to October 2003.

The fifth report of the ESHRE PGD Consortium is presented (data collection V). For the first time, the cycle data were collected for one calendar year (2002) in the following October, so that data collection was complete for pregnancies and babies. The data were collected using a Filemaker Pro database and divided into referrals, cycles, pregnancies and babies. There are currently 66 active centres registered with the consortium; however, the data presented here were obtained from 43 centres and included 1603 referrals, 2219 cycles, 485 pregnancies and 382 babies born. The cycle data were divided into preimplantation genetic diagnosis (PGD) for inherited disorders (including chromosome abnormalities, sexing for X-linked disease and monogenic disorders), aneuploidy screening (PGS) and the use of PGD for social sexing. Data collection V is compared with the previous cumulative data collection (I-IV), which comprised 4058 PGD/PGS cycles that reached oocyte retrieval.

Aneuploidy↗

PubMed2004

ESHRE PGD Consortium 'Best practice guidelines for clinical preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS)'.

Among the many educational materials produced by the European Society of Human Reproduction and Embryology (ESHRE) are guidelines. ESHRE guidelines may be developed for many reasons but their intent is always to promote best quality practices in reproductive medicine. In an era in which preimplantation genetic diagnosis (PGD) has become a reality, we must strive to maintain its efficacy and credibility by offering the safest and most effective treatment available. The dominant motivators for the development of current comprehensive guidelines for best PGD practice were (i) the absence of guidelines and/or regulation for PGD in many countries and (ii) the observation that no consensus exists on many of the clinical and technical aspects of PGD. As a consequence, the ESHRE PGD Consortium undertook to draw up guidelines aimed at giving information, support and guidance to potential, fledgling and established PGD centres. The success of a PGD treatment cycle is the result of great attention to detail. We have strived to provide a similar level of detail in this document and hope that it will assist staff in achieving the best clinical outcome for their patients.

Biopsy↗